A Phase 2 interventional study of Ublituximab and Placebo in Multiple Sclerosis, sponsored by TG Therapeutics, Inc.. Completed at 12 sites in United States. Open to participants aged 18 Years to 55 Years. Per ClinicalTrials.gov, last updated 2021-07-15.
Sponsored by TG Therapeutics, Inc. · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies testing ublituximab in Multiple Sclerosis — 5 open to participants now, 7 under way, 4 of them phase 3. ublituximab · Multiple Sclerosis.
Among the 10 studies testing ublituximab in Multiple Sclerosis, this one is the 9th largest by enrollment, is the only one that started in 2016, is one of 2 in phase 2, and was the 1st registered.
3,271 studies on the registry are indexed under Multiple Sclerosis; 665 are open to participants now.
Browse Multiple Sclerosis studies →5 of the 10 studies testing ublituximab in Multiple Sclerosis are open now, in 8 countries. Recruiting first, the newest first:
TG Therapeutics, Inc. · Sites in United States, Poland, Slovakia
Ages 10–17
TG Therapeutics, Inc. · Sites in Bosnia and Herzegovina, Georgia, North Macedonia and 3 more countries
Ages 18–65
Johns Hopkins University · Sites in United States
Ages 18–65
Northwestern University · Sites in United States
Ages 18–70
TG Therapeutics, Inc. · Sites in United States, Poland
Ages 18–65
By country, each count listing its studies:
ublituximab: first FDA approval 2022 (BRIUMVI), first EMA approval 2023. What it is approved for, and how studies give it, is on its page →
Of the 433 Multiple Sclerosis studies recruiting now, 163 (38%) set no upper age limit and 214 (49%) stop at 75 or younger; 40 take children under 18; 96 take healthy volunteers.
This study: 18 Years to 55 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 3 · Phase 3 6 · Phase 4 2
First in 2016; this study’s year is marked. 1 started in 2016.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 49 is close to the median of 50 across 2,207 interventional studies indexed under Multiple Sclerosis.
Median enrollment 355 across the 10 interventional studies. Of the 3 that completed or were terminated, 3 (100%) have results posted.
This tab as a report to print or save as PDF → With an account.
8 of 10 have an industry lead sponsor. The 3 most frequent:
TG Therapeutics, Inc. is the lead sponsor of 40 studies on the registry; 9 are open to participants now.
Of its 16 completed or terminated interventional studies of FDA-regulated products, 9 (56%) have results posted.
12 studies in Multiple Sclerosis by TG Therapeutics, Inc.: 6 open now, 9 under way, 4 of them phase 3. Of 3 finished, 3 (100%) have results posted.
Among the 12 studies in Multiple Sclerosis by TG Therapeutics, Inc., this one is the only one that started in 2016, is one of 2 in phase 2, and was the 1st registered.
TG Therapeutics, Inc.’s Multiple Sclerosis studies by the year they started, since 2016.
2 of the studies testing ublituximab in Multiple Sclerosis that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05877963Phase 3TG Therapeutics, Inc.Study to Evaluate Safety, Efficacy and Pharmacokinetics (PK) of a Modified Regimen of Ublituximab | 2027-01-21 |
| NCT07503873TG Therapeutics, Inc.A Study to Evaluate Pharmacokinetics (PK) and Safety of Subcutaneous (SC) Ublituximab Administered at Various Injection Sites and Relative Bioavailability Via Autoinjector (AI) Versus Syringe Subcutaneously in Participants With Multiple Sclerosis (MS) | 2027-07-31 |
Add all 2 to your calendar (.ics) → With an account.
Among the 10 studies testing ublituximab in Multiple Sclerosis, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among TG Therapeutics, Inc.’s 12 in Multiple Sclerosis:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study evaluates the use of single agent ublituximab, a novel monoclonal antibody, in participants with relapsing forms of multiple sclerosis.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Participant received intravenous (IV) infusion of ublituximab 150 milligrams (mg)/4 hour (hr) on Day 1, 450 mg/3 hr on Day 15 and 450 mg/1.5 hr on Week 24. Some participants initially received placebo IV infusion /4 hr on Day 1 and /3 hr on Day 15 before receiving ublituximab.
Biological: Ublituximab · Drug: Placebo
Participant received IV infusion of ublituximab 150 mg/4 hr on Day 1, 450 mg/1.5 hr on Day 15 and 450 mg/1 hr on Week 24. Some participants initially received placebo IV infusion /4 hr on Day 1 and /1.5 hr on Day 15 before receiving ublituximab.
Biological: Ublituximab · Drug: Placebo
Participant received IV infusion of ublituximab 150 mg/4 hr on Day 1, 450 mg/1 hr on Day 15 and 600 mg/1 hr on Week 24. Some participants initially received placebo IV infusion /4 hr on Day 1 and /1 hr on Day 15 before receiving ublituximab.
Biological: Ublituximab · Drug: Placebo
Participant received IV infusion of ublituximab 150 mg/3 hr on Day 1, 600 mg/1 hr on Day 15 and 600 mg/1 hr on Week 24. Some participants initially received placebo IV infusion /3 hr on Day 1 and /1 hr on Day 15 before receiving ublituximab.
Biological: Ublituximab · Drug: Placebo
Participant received IV infusion of ublituximab 150 mg/2 hr on Day 1, 600 mg/1 hr on Day 15 and 600 mg/1 hr on Week 24. Some participants initially received placebo IV infusion /2 hr on Day 1 and /1 hr on Day 15 before receiving ublituximab.
Biological: Ublituximab · Drug: Placebo
Participant received IV infusion of ublituximab 150 mg/1 hr on Day 1, 600 mg/1 hr on Day 15 and 600 mg/1 hr on Week 24. Some participants initially received placebo IV infusion /1 hr on Day 1 and /1 hr on Day 15 before receiving ublituximab.
Biological: Ublituximab · Drug: Placebo
Administered as an IV infusion.
Also known as: TG-1101
Responder Rate of B-Cell Depletion at Week 4
Responders Rate is defined as percentage of participants with greater than or equal to (≥) 95% reduction of B cells (cluster of differentiation 19 positive \[CD19+\] cells) within 2 weeks after the second infusion (Day 15).
Time frame: Week 4
Number of New Gadolinium (Gd)-Enhancing T1 Lesions at Weeks 24 and 48
The Gd-enhancing T1 lesions were evaluated using magnetic resonance imaging (MRI) technique.
Time frame: Weeks 24 and 48
Number of New or Enlarging T2 Lesions at Weeks 24 and 48
The new or enlarging T2 lesions were evaluated using MRI technique.
Time frame: Weeks 24 and 48
Annualized Relapse Rate (ARR)
ARR at Week 48 is calculated as the ratio of the sum of all participants confirmed relapse counts divided by the sum of all participants treatment duration (in years).
Time frame: Week 48
Relapse Rate Reduction (RRR)
RRR was calculated as the percentage reduction from baseline ARR to ARR at Week 48.
Time frame: Baseline to Week 48
Percentage of Relapse Free Participants
Participant was considered as free of clinical relapse if participant had no confirmed clinical relapse before treatment discontinuation/until end of Week 48. Relapses are defined as the occurrence of new or worsening neurological symptoms attributable to multiple sclerosis (MS), and immediately preceded by a stable or improving neurological state of at least 30 days.
Time frame: Week 48
Change From Baseline in B Cells (CD19+), Memory (CD19+CD27+) and Naïve (CD19+CD27-[Negative]) B Cells
Cluster of Differentiation (CD)19 is a marker of B cells, the protein has been used to diagnose cancers that arise from this type of cell - notably B cell lymphomas, acute lymphoblastic leukemia (ALL), and chronic lymphocytic leukemia (CLL). The majority of B cell malignancies express normal to high levels of CD19. Memory B cell is a type of B lymphocyte that forms part of the adaptive immune system. These cells develop within germinal centers of the secondary lymphoid organs. Their function is to memorize the characteristics of the antigen that activated their parent B cell during initial infection such that if the memory B cell later encounters the same antigen, it triggers an accelerated and robust secondary immune response. A naive B cell is a B cell that has not been exposed to an antigen. Once exposed to an antigen, the naive B cell either becomes a memory B cell or a plasma cell that secretes antibodies specific to the antigen that was originally bound.
Time frame: Baseline, Week 1 Day 2, Week 2, Week 3 Day 15, Weeks 4, 8, 12, 16, 20, 24, Week 24 plus 2 days, Weeks 25, 28, 36, 40, 44 and 48
Change From Baseline in Sustained B Cell
Sustained B cell reduction is defined as B-cell reductions achieved on pre-dose at Week 24 and Week 48.
Time frame: Baseline to pre-dose at Week 24 and Week 48
Additional Immune Profiling-CD4+ (Cluster of Differentiation 4 Positive)
A blood sample was collected and was sent to the laboratory for analysis of CD4+.
Time frame: Baseline, Week 1 Day 2, Week 2, Week 3 Day 15, Weeks 4, 8, 12, 16, 20, 24, Week 24 Plus 2 Days, Weeks 25, 28, 36, 40, 44 and 48
Additional Immune Profiling-CD8+ (Cluster of Differentiation 8 Positive)
A blood sample was collected and was sent to the laboratory for analysis of CD8+.
Time frame: Baseline, Week 1 Day 2, Week 2, Week 3 Day 15, Weeks 4, 8, 12, 16, 20, 24, Week 24 Plus 2 Days, Weeks 25, 28, 36, 40, 44 and 48
Additional Immune Profiling-Interleukin 10 (IL10)
A blood sample was collected and was sent to the laboratory for analysis of IL-10. IL-10 is an anti-inflammatory cytokine that maintains the balance of the immune response, allowing the clearance of infection while minimizing damage to the host.
Time frame: Baseline, Weeks 2, 4, 12, 20, 24, 25, 36, 44 and 48
Additional Immune Profiling-Natural Killer (NK) Cells
A blood sample was collected and was sent to the laboratory for analysis of NK cells. Percentage of NK cells per ml of blood. NK cells are lymphocytes with the ability to kill tumor cells without deliberate immunization or activation.
Time frame: Baseline, Week 1 Day 2, Week 2, Week 3 Day 15, Weeks 4, 8, 12, 16, 20, 24, Week 24 Plus 2 Days, Weeks 25, 28, 36, 40, 44 and 48
Pharmacokinetic Parameter: Plasma Concentration of Ublituximab
Plasma concentration is defined as the measured concentration of ublituximab.
Time frame: Day 1 (pre-dose); Week 2; Day 15 (pre-dose); Weeks 4, 24 (pre-dose) and 25
| Milestone | Cohort 1 | Cohort 2 | Cohort 3 | Cohort 4 | Cohort 5 | Cohort 6 |
|---|---|---|---|---|---|---|
| Started | 8 | 8 | 8 | 9 | 8 | 8 |
| Initially treated with placebo | 0 | 0 | 0 | 1 | 0 | 0 |
| Completed | 8 | 6 | 8 | 8 | 8 | 7 |
| Not completed | 0 | 2 | 0 | 1 | 0 | 1 |
| Withdrew: Withdrawal by subject | 0 | 1 | 0 | 0 | 0 | 0 |
| Withdrew: Adverse event | 0 | 0 | 0 | 1 | 0 | 0 |
| Withdrew: Pregnancy | 0 | 1 | 0 | 0 | 0 | 0 |
| Withdrew: Missing | 0 | 0 | 0 | 0 | 0 | 1 |
Responders Rate is defined as percentage of participants with greater than or equal to (≥) 95% reduction of B cells (cluster of differentiation 19 positive \[CD19+\] cells) within 2 weeks after the second infusion (Day 15).
| percentage of participants | Cohort 1 | Cohort 2 | Cohort 3 | Cohort 4 | Cohort 5 | Cohort 6 |
|---|---|---|---|---|---|---|
| Responder Rate of B-Cell Depletion at Week 4 | 87.5 (47.35 to 99.68) | 100.0 (63.06 to 100) | 87.5 (47.35 to 99.68) | 100.0 (63.06 to 100) | 100.0 (63.06 to 100) | 100.0 (63.06 to 100) |
The Gd-enhancing T1 lesions were evaluated using magnetic resonance imaging (MRI) technique.
| lesions | Cohort 1 | Cohort 2 | Cohort 3 | Cohort 4 | Cohort 5 | Cohort 6 |
|---|---|---|---|---|---|---|
| Week 24 | 0.0 ± 0.00 | 0.0 ± 0.00 | 0.0 ± 0.00 | 0.0 ± 0.00 | 0.0 ± 0.00 | 0.0 ± 0.00 |
| Week 48 | 0.0 ± 0.00 | 0.0 ± 0.00 | 0.0 ± 0.00 | 0.0 ± 0.00 | 0.0 ± 0.00 | 0.0 ± 0.00 |
The new or enlarging T2 lesions were evaluated using MRI technique.
| lesions | Cohort 1 | Cohort 2 | Cohort 3 | Cohort 4 | Cohort 5 | Cohort 6 |
|---|---|---|---|---|---|---|
| Week 24 | 0.38 ± 0.52 | 0.29 ± 0.49 | 0.00 ± 0.00 | 0.25 ± 0.71 | 0.00 ± 0.00 | 0.14 ± 0.38 |
| Week 48 | 0.25 ± 0.71 | 0.00 ± 0.00 | 0.00 ± 0.00 | 0.00 ± 0.00 | 0.00 ± 0.00 | 0.00 ± 0.00 |
ARR at Week 48 is calculated as the ratio of the sum of all participants confirmed relapse counts divided by the sum of all participants treatment duration (in years).
| relapses per participant-years | Cohort 1 | Cohort 2 | Cohort 3 | Cohort 4 | Cohort 5 | Cohort 6 |
|---|---|---|---|---|---|---|
| Annualized Relapse Rate (ARR) | 0.28 | 0.00 | 0.14 | 0.14 | 0.00 | 0.00 |
RRR was calculated as the percentage reduction from baseline ARR to ARR at Week 48.
| percentage reduction | Cohort 1 | Cohort 2 | Cohort 3 | Cohort 4 | Cohort 5 | Cohort 6 |
|---|---|---|---|---|---|---|
| Relapse Rate Reduction (RRR) | 75.55 | 100.00 | 87.80 | 89.04 | 100.00 | 100.00 |
Participant was considered as free of clinical relapse if participant had no confirmed clinical relapse before treatment discontinuation/until end of Week 48. Relapses are defined as the occurrence of new or worsening neurological symptoms attributable to multiple sclerosis (MS), and immediately preceded by a stable or improving neurological state of at least 30 days.
| percentage of participants | Cohort 1 | Cohort 2 | Cohort 3 | Cohort 4 | Cohort 5 | Cohort 6 |
|---|---|---|---|---|---|---|
| Percentage of Relapse Free Participants | 75.0 (34.91 to 96.81) | 100.0 (63.06 to 100) | 87.5 (47.35 to 99.68) | 87.5 (47.35 to 99.68) | 100.0 (63.06 to 100) | 100.0 (63.06 to 100) |
Cluster of Differentiation (CD)19 is a marker of B cells, the protein has been used to diagnose cancers that arise from this type of cell - notably B cell lymphomas, acute lymphoblastic leukemia (ALL), and chronic lymphocytic leukemia (CLL). The majority of B cell malignancies express normal to high levels of CD19. Memory B cell is a type of B lymphocyte that forms part of the adaptive immune system. These cells develop within germinal centers of the secondary lymphoid organs. Their function is to memorize the characteristics of the antigen that activated their parent B cell during initial infection such that if the memory B cell later encounters the same antigen, it triggers an accelerated and robust secondary immune response. A naive B cell is a B cell that has not been exposed to an antigen. Once exposed to an antigen, the naive B cell either becomes a memory B cell or a plasma cell that secretes antibodies specific to the antigen that was originally bound.
| percentage of cells | Cohort 1 | Cohort 2 | Cohort 3 | Cohort 4 | Cohort 5 | Cohort 6 |
|---|---|---|---|---|---|---|
| B Cells (CD19+): Baseline | 7.40 ± 4.108 | 7.89 ± 3.899 | 7.24 ± 4.586 | 8.11 ± 2.696 | 5.71 ± 2.368 | 6.78 ± 2.097 |
| B Cells (CD19+): Change from Baseline to Week 1 Day 2 | -6.55 ± 3.920 | -8.29 ± 3.850 | -6.54 ± 4.715 | -7.95 ± 2.719 | -5.66 ± 2.347 | -6.70 ± 2.123 |
| B Cells (CD19+): Change from Baseline to Week 2 | -7.52 ± 3.175 | -7.80 ± 3.878 | -7.13 ± 4.617 | -6.95 ± 1.806 | -5.68 ± 2.362 | -6.73 ± 2.090 |
| B Cells (CD19+): Change from Baseline to Week 3 Day 15 | -7.27 ± 4.053 | -7.80 ± 3.830 | -7.17 ± 4.592 | -8.03 ± 2.714 | -5.69 ± 2.369 | -6.72 ± 2.080 |
| B Cells (CD19+): Change from Baseline to Week 4 | -7.28 ± 4.127 | -7.79 ± 3.859 | -6.82 ± 4.889 | -8.03 ± 2.717 | -6.03 ± 2.322 | -6.71 ± 2.102 |
| B Cells (CD19+): Change from Baseline to Week 8 | -7.29 ± 4.102 | -7.79 ± 3.886 | -7.15 ± 4.625 | -8.03 ± 3.032 | -5.69 ± 2.358 | -6.70 ± 2.065 |
| B Cells (CD19+): Change from Baseline to Week 12 | -7.47 ± 4.592 | -7.77 ± 3.823 | -7.17 ± 4.617 | -8.45 ± 2.644 | -5.35 ± 2.317 | -7.14 ± 1.820 |
| B Cells (CD19+): Change from Baseline to Week 16 | -7.01 ± 4.352 | -7.53 ± 4.110 | -7.75 ± 4.628 | -7.83 ± 2.667 | -5.68 ± 2.375 | -6.89 ± 2.178 |
| B Cells (CD19+): Change from Baseline to Week 20 | -7.23 ± 4.116 | -8.07 ± 4.449 | -7.18 ± 4.637 | -7.58 ± 2.740 | -5.70 ± 2.534 | -6.65 ± 2.200 |
| B Cells (CD19+): Change from Baseline to Week 24 | -7.21 ± 4.068 | -7.53 ± 3.399 | -7.76 ± 4.478 | -7.39 ± 2.940 | -5.65 ± 2.377 | -5.62 ± 1.992 |
| B Cells (CD19+): Change from Baseline to Week 24 Plus 2 Days | -7.31 ± 4.108 | -6.45 ± 2.919 | -7.98 ± 4.430 | -7.88 ± 2.895 | -6.29 ± 2.403 | -7.47 ± 1.983 |
| B Cells (CD19+): Change from Baseline to Week 25 | -6.45 ± 3.698 | -8.20 ± 4.007 | -7.88 ± 4.512 | -8.06 ± 2.694 | -5.57 ± 2.544 | -7.47 ± 2.008 |
| B Cells (CD19+): Change from Baseline to Week 28 | -7.31 ± 4.106 | -6.81 ± 2.844 | -7.18 ± 4.597 | -8.00 ± 2.699 | -5.65 ± 2.360 | -6.64 ± 2.258 |
| B Cells (CD19+): Change from Baseline to Week 36 | -7.32 ± 4.082 | -6.79 ± 2.820 | -7.18 ± 4.601 | -8.48 ± 2.905 | -5.69 ± 2.530 | -6.64 ± 2.255 |
| B Cells (CD19+): Change from Baseline to Week 40 | -5.40 ± 3.828 | -6.74 ± 2.838 | -7.15 ± 4.567 | -7.77 ± 3.132 | -5.65 ± 2.343 | -6.56 ± 2.299 |
| B Cells (CD19+): Change from Baseline to Week 44 | -7.32 ± 4.092 | -6.74 ± 2.801 | -7.05 ± 4.546 | -8.06 ± 2.860 | -5.65 ± 2.341 | -6.59 ± 2.296 |
| B Cells (CD19+): Change from Baseline to Week 48 | -7.25 ± 4.086 | -6.71 ± 2.854 | -6.87 ± 4.542 | -7.73 ± 2.621 | -5.67 ± 2.342 | -7.39 ± 2.174 |
| Memory (CD19+CD27+): Baseline | 0.38 ± 0.337 | 0.92 ± 0.722 | 0.90 ± 1.010 | 0.68 ± 0.457 | 0.88 ± 0.997 | 0.60 ± 0.367 |
| Memory (CD19+CD27+): Change from Baseline to Week 1 Day 2 | -0.28 ± 0.279 | -0.92 ± 0.728 | -0.90 ± 1.098 | -0.59 ± 0.480 | -0.85 ± 1.001 | -0.54 ± 0.357 |
| Memory (CD19+CD27+): Change from Baseline to Week 2 | -0.32 ± 0.354 | -0.86 ± 0.713 | -0.83 ± 1.032 | -0.46 ± 0.411 | -0.86 ± 1.003 | -0.57 ± 0.357 |
| Memory (CD19+CD27+): Change from Baseline to Week 3 Day 15 | -0.31 ± 0.285 | -0.86 ± 0.694 | -0.86 ± 1.007 | -0.63 ± 0.468 | -0.87 ± 1.001 | -0.57 ± 0.382 |
| Memory (CD19+CD27+): Change from Baseline to Week 4 | -0.31 ± 0.347 | -0.85 ± 0.690 | -0.64 ± 0.910 | -0.64 ± 0.465 | -0.91 ± 1.072 | -0.55 ± 0.396 |
| Memory (CD19+CD27+): Change from Baseline to Week 8 | -0.32 ± 0.331 | -0.86 ± 0.736 | -0.85 ± 1.030 | -0.64 ± 0.552 | -0.87 ± 0.994 | -0.55 ± 0.381 |
| Memory (CD19+CD27+): Change from Baseline to Week 12 | -0.36 ± 0.364 | -0.83 ± 0.668 | -0.87 ± 1.019 | -0.69 ± 0.494 | -0.92 ± 1.068 | -0.60 ± 0.381 |
| Memory (CD19+CD27+): Change from Baseline to Week 16 | -0.30 ± 0.355 | -0.92 ± 0.769 | -0.93 ± 1.068 | -0.65 ± 0.456 | -0.87 ± 1.004 | -0.56 ± 0.427 |
| Memory (CD19+CD27+): Change from Baseline to Week 20 | -0.27 ± 0.335 | -0.86 ± 0.849 | -1.07 ± 1.101 | -0.64 ± 0.431 | -0.88 ± 1.064 | -0.52 ± 0.421 |
| Memory (CD19+CD27+): Change from Baseline to Week 24 | -0.30 ± 0.340 | -0.84 ± 0.656 | -0.96 ± 1.038 | -0.69 ± 0.442 | -0.86 ± 1.007 | -0.59 ± 0.444 |
| Memory (CD19+CD27+): Change from Baseline to Week 24 Plus 2 Days | -0.34 ± 0.330 | -0.74 ± 0.434 | -0.76 ± 0.875 | -0.59 ± 0.469 | -0.91 ± 1.168 | -0.65 ± 0.469 |
| Memory (CD19+CD27+): Change from Baseline to Week 25 | -0.28 ± 0.371 | -0.97 ± 0.738 | -0.98 ± 1.057 | -0.65 ± 0.465 | -0.95 ± 1.033 | -0.61 ± 0.404 |
| Memory (CD19+CD27+): Change from Baseline to Week 28 | -0.34 ± 0.336 | -0.68 ± 0.442 | -0.87 ± 1.021 | -0.62 ± 0.508 | -0.85 ± 0.971 | -0.60 ± 0.368 |
| Memory (CD19+CD27+): Change from Baseline to Week 36 | -0.34 ± 0.322 | -0.68 ± 0.436 | -0.87 ± 1.020 | -0.75 ± 0.495 | -0.88 ± 1.069 | -0.59 ± 0.400 |
| Memory (CD19+CD27+): Change from Baseline to Week 40 | -0.20 ± 0.086 | -0.68 ± 0.441 | -0.86 ± 1.012 | -0.62 ± 0.450 | -0.85 ± 0.975 | -0.57 ± 0.424 |
| Memory (CD19+CD27+): Change from Baseline to Week 44 | -0.34 ± 0.341 | -0.66 ± 0.429 | -0.85 ± 0.997 | -0.69 ± 0.462 | -0.85 ± 1.008 | -0.62 ± 0.444 |
| Memory (CD19+CD27+): Change from Baseline to Week 48 | -0.32 ± 0.344 | -0.65 ± 0.463 | -0.83 ± 0.983 | -0.62 ± 0.433 | -0.86 ± 1.007 | -0.71 ± 0.414 |
| Naïve (CD19+CD27-): Baseline | 6.92 ± 3.837 | 7.30 ± 3.188 | 6.26 ± 4.043 | 7.00 ± 2.135 | 4.73 ± 2.206 | 6.11 ± 2.096 |
| Naïve (CD19+CD27-): Change from Baseline to Week 1 Day 2 | -6.18 ± 3.665 | -7.29 ± 3.427 | -5.56 ± 3.954 | -6.93 ± 2.132 | -4.72 ± 2.203 | -6.09 ± 2.100 |
| Naïve (CD19+CD27-): Change from Baseline to Week 2 | -7.09 ± 2.899 | -7.27 ± 3.177 | -6.23 ± 4.058 | -6.18 ± 1.723 | -4.73 ± 2.205 | -6.10 ± 2.089 |
| Naïve (CD19+CD27-): Change from Baseline to Week 3 Day 15 | -6.86 ± 3.805 | -7.27 ± 3.161 | -6.23 ± 4.043 | -6.97 ± 2.137 | -4.73 ± 2.205 | -6.09 ± 2.081 |
| Naïve (CD19+CD27-): Change from Baseline to Week 4 | -6.87 ± 3.836 | -7.26 ± 3.173 | -6.13 ± 4.342 | -6.96 ± 2.134 | -5.02 ± 2.211 | -6.09 ± 2.092 |
| Naïve (CD19+CD27-): Change from Baseline to Week 8 | -6.88 ± 3.831 | -7.26 ± 3.173 | -6.22 ± 4.057 | -6.99 ± 2.322 | -4.73 ± 2.203 | -6.08 ± 2.093 |
| Naïve (CD19+CD27-): Change from Baseline to Week 12 | -7.00 ± 4.287 | -7.26 ± 3.175 | -6.23 ± 4.061 | -7.29 ± 2.060 | -4.36 ± 2.100 | -6.47 ± 1.907 |
| Naïve (CD19+CD27-): Change from Baseline to Week 16 | -6.61 ± 4.067 | -7.00 ± 3.341 | -6.74 ± 4.085 | -6.76 ± 2.098 | -4.73 ± 2.209 | -6.27 ± 2.184 |
| Naïve (CD19+CD27-): Change from Baseline to Week 20 | -6.87 ± 3.828 | -7.67 ± 3.234 | -6.02 ± 3.994 | -6.52 ± 2.214 | -4.73 ± 2.377 | -6.06 ± 2.139 |
| Naïve (CD19+CD27-): Change from Baseline to Week 24 | -6.81 ± 3.788 | -7.02 ± 2.809 | -6.71 ± 4.024 | -6.26 ± 2.275 | -4.71 ± 2.207 | -4.96 ± 1.658 |
| Naïve (CD19+CD27-): Change from Baseline to Week 24 Plus 2 Days | -6.87 ± 3.842 | -6.18 ± 2.666 | -7.15 ± 4.231 | -6.81 ± 2.272 | -5.28 ± 2.286 | -6.74 ± 2.156 |
| Naïve (CD19+CD27-): Change from Baseline to Week 25 | -6.13 ± 3.473 | -7.61 ± 3.257 | -6.81 ± 4.012 | -6.98 ± 2.132 | -4.52 ± 2.305 | -6.74 ± 2.148 |
| Naïve (CD19+CD27-): Change from Baseline to Week 28 | -6.87 ± 3.837 | -6.53 ± 2.612 | -6.24 ± 4.047 | -6.95 ± 2.139 | -4.71 ± 2.208 | -5.97 ± 2.235 |
| Naïve (CD19+CD27-): Change from Baseline to Week 36 | -6.89 ± 3.830 | -6.52 ± 2.594 | -6.23 ± 4.051 | -7.22 ± 2.249 | -4.72 ± 2.374 | -5.97 ± 2.233 |
| Naïve (CD19+CD27-): Change from Baseline to Week 40 | -5.18 ± 3.740 | -6.46 ± 2.565 | -6.21 ± 4.042 | -6.63 ± 2.419 | -4.72 ± 2.204 | -5.92 ± 2.266 |
| Naïve (CD19+CD27-): Change from Baseline to Week 44 | -6.89 ± 3.831 | -6.48 ± 2.573 | -6.13 ± 4.050 | -6.98 ± 2.283 | -4.72 ± 2.204 | -5.94 ± 2.248 |
| Naïve (CD19+CD27-): Change from Baseline to Week 48 | -6.83 ± 3.809 | -6.46 ± 2.580 | -5.96 ± 4.091 | -6.69 ± 2.060 | -4.73 ± 2.205 | -6.60 ± 2.292 |
Sustained B cell reduction is defined as B-cell reductions achieved on pre-dose at Week 24 and Week 48.
| percentage of cells | Cohort 1 | Cohort 2 | Cohort 3 | Cohort 4 | Cohort 5 | Cohort 6 |
|---|---|---|---|---|---|---|
| Baseline | 7.40 ± 4.108 | 7.89 ± 3.899 | 7.24 ± 4.586 | 8.11 ± 2.696 | 5.71 ± 2.368 | 6.78 ± 2.097 |
| Change at Pre-dose at Week 24 | -7.21 ± 4.068 | -7.53 ± 3.399 | -7.76 ± 4.478 | -7.39 ± 2.940 | -5.65 ± 2.377 | -5.62 ± 1.992 |
| Change at Pre-dose at Week 48 | -7.25 ± 4.086 | -6.71 ± 2.854 | -6.87 ± 4.542 | -7.73 ± 2.621 | -5.67 ± 2.342 | -7.39 ± 2.174 |
A blood sample was collected and was sent to the laboratory for analysis of CD4+.
| cells per cubic millimeter (cells/mm^3) | Cohort 1 | Cohort 2 | Cohort 3 | Cohort 4 | Cohort 5 | Cohort 6 |
|---|---|---|---|---|---|---|
| Baseline | 28.73 ± 12.195 | 35.39 ± 4.628 | 24.34 ± 12.877 | 25.75 ± 6.874 | 22.70 ± 9.488 | 22.27 ± 10.588 |
| Week 1 Day 2 | 22.71 ± 15.829 | 27.52 ± 11.388 | 19.51 ± 9.129 | 16.98 ± 11.624 | 16.49 ± 13.985 | 14.15 ± 5.911 |
| Week 2 | 34.01 ± 7.190 | 39.83 ± 8.829 | 33.31 ± 4.862 | 36.51 ± 9.289 | 28.50 ± 8.173 | 25.69 ± 8.761 |
| Week 3 Day 15 | 23.74 ± 11.399 | 26.51 ± 10.650 | 22.60 ± 7.766 | 27.68 ± 13.656 | 19.88 ± 13.902 | 24.57 ± 11.080 |
| Week 4 | 26.19 ± 11.922 | 35.31 ± 11.530 | 31.47 ± 8.658 | 30.97 ± 12.840 | 24.62 ± 8.087 | 27.59 ± 11.016 |
| Week 8 | 29.74 ± 15.735 | 31.46 ± 8.387 | 29.64 ± 8.204 | 30.95 ± 14.625 | 27.73 ± 9.162 | 24.59 ± 4.511 |
| Week 12 | 24.20 ± 8.152 | 32.26 ± 7.118 | 30.98 ± 11.476 | 27.71 ± 9.209 | 28.03 ± 12.045 | 24.09 ± 8.087 |
| Week 16 | 24.03 ± 10.040 | 31.55 ± 7.557 | 19.19 ± 10.466 | 31.27 ± 12.131 | 27.37 ± 14.733 | 17.85 ± 4.155 |
| Week 20 | 22.94 ± 9.492 | 26.87 ± 11.629 | 34.25 ± 8.928 | 33.56 ± 8.537 | 27.17 ± 7.908 | 24.51 ± 13.149 |
| Week 24 | 29.24 ± 8.678 | 29.36 ± 8.856 | 31.33 ± 13.406 | 29.12 ± 7.006 | 26.71 ± 9.603 | 17.41 ± 7.523 |
| Week 24 Plus 2 Days | 26.25 ± 8.120 | 27.54 ± 5.269 | 22.82 ± 17.385 | 36.47 ± 12.548 | 23.59 ± 6.912 | 21.22 ± 8.474 |
| Week 25 | 30.70 ± 8.594 | 27.31 ± 13.091 | 35.42 ± 8.854 | 28.46 ± 9.801 | 27.96 ± 6.024 | 17.57 ± 10.438 |
| Week 28 | 20.03 ± 11.870 | 31.70 ± 13.654 | 29.71 ± 13.051 | 23.57 ± 10.565 | 23.09 ± 8.855 | 21.64 ± 14.610 |
| Week 36 | 26.79 ± 14.209 | 28.06 ± 9.436 | 37.56 ± 8.664 | 22.86 ± 8.413 | 14.73 ± 5.916 | 28.20 ± 15.386 |
| Week 40 | 25.31 ± 10.664 | 30.91 ± 10.601 | 28.45 ± 11.497 | 28.10 ± 9.464 | 18.17 ± 11.192 | 26.68 ± 17.744 |
| Week 44 | 24.77 ± 6.469 | 29.84 ± 9.013 | 29.83 ± 10.774 | 17.17 ± 9.920 | 26.22 ± 14.340 | 28.24 ± 12.190 |
| Week 48 | 26.72 ± 6.914 | 32.92 ± 6.697 | 21.90 ± 7.779 | 22.60 ± 8.935 | 30.85 ± 13.016 | 27.03 ± 7.844 |
A blood sample was collected and was sent to the laboratory for analysis of CD8+.
| cells/mm^3 | Cohort 1 | Cohort 2 | Cohort 3 | Cohort 4 | Cohort 5 | Cohort 6 |
|---|---|---|---|---|---|---|
| Baseline | 16.80 ± 5.324 | 17.50 ± 5.222 | 9.97 ± 4.877 | 12.25 ± 2.374 | 8.72 ± 3.590 | 12.83 ± 6.576 |
| Week 1 Day 2 | 10.04 ± 6.698 | 12.06 ± 6.524 | 6.87 ± 2.746 | 5.93 ± 2.748 | 5.14 ± 2.779 | 7.61 ± 5.157 |
| Week 2 | 17.03 ± 3.654 | 16.96 ± 7.869 | 13.22 ± 3.141 | 14.68 ± 2.377 | 11.14 ± 4.767 | 14.22 ± 9.157 |
| Week 3 Day 15 | 12.14 ± 6.646 | 11.88 ± 6.580 | 9.21 ± 4.780 | 12.10 ± 6.033 | 7.22 ± 4.103 | 12.50 ± 6.536 |
| Week 4 | 13.89 ± 5.715 | 14.89 ± 7.815 | 11.78 ± 3.263 | 13.70 ± 5.296 | 9.89 ± 2.120 | 13.49 ± 5.214 |
| Week 8 | 15.92 ± 8.489 | 13.91 ± 5.074 | 10.97 ± 3.012 | 12.80 ± 7.567 | 9.63 ± 3.056 | 12.62 ± 5.613 |
| Week 12 | 15.21 ± 8.122 | 17.21 ± 6.807 | 11.83 ± 5.397 | 11.06 ± 3.773 | 8.93 ± 4.185 | 14.87 ± 9.608 |
| Week 16 | 16.25 ± 6.951 | 13.87 ± 7.431 | 6.76 ± 3.613 | 12.51 ± 3.827 | 10.63 ± 6.203 | 10.86 ± 5.193 |
| Week 20 | 15.04 ± 7.197 | 10.35 ± 5.998 | 10.04 ± 3.132 | 13.71 ± 3.450 | 10.29 ± 5.150 | 12.98 ± 7.476 |
| Week 24 | 15.83 ± 4.047 | 13.77 ± 5.509 | 11.59 ± 5.417 | 12.22 ± 5.372 | 12.05 ± 6.859 | 9.45 ± 6.093 |
| Week 24 Plus 2 Days | 14.70 ± 3.655 | 13.28 ± 6.727 | 7.05 ± 4.656 | 15.52 ± 5.839 | 8.90 ± 1.508 | 9.41 ± 3.298 |
| Week 25 | 15.38 ± 6.717 | 12.48 ± 4.475 | 12.07 ± 4.773 | 11.60 ± 4.172 | 9.78 ± 2.395 | 8.94 ± 6.287 |
| Week 28 | 11.15 ± 4.599 | 12.84 ± 5.522 | 10.63 ± 6.617 | 11.02 ± 3.030 | 9.32 ± 2.121 | 9.71 ± 3.160 |
| Week 36 | 12.92 ± 7.721 | 11.95 ± 5.493 | 12.46 ± 2.840 | 10.11 ± 4.527 | 6.92 ± 3.158 | 11.59 ± 2.584 |
| Week 40 | 14.63 ± 3.687 | 12.77 ± 7.654 | 9.82 ± 3.926 | 11.59 ± 4.485 | 7.93 ± 2.207 | 10.30 ± 4.027 |
| Week 44 | 14.41 ± 6.085 | 11.46 ± 2.451 | 9.91 ± 3.937 | 8.67 ± 5.073 | 9.59 ± 3.922 | 11.87 ± 3.352 |
| Week 48 | 13.28 ± 6.673 | 12.79 ± 5.232 | 7.42 ± 2.276 | 9.86 ± 5.260 | 11.68 ± 5.757 | 13.50 ± 3.412 |
A blood sample was collected and was sent to the laboratory for analysis of IL-10. IL-10 is an anti-inflammatory cytokine that maintains the balance of the immune response, allowing the clearance of infection while minimizing damage to the host.
| picogram per milliliter (pg/ml) | Cohort 1 | Cohort 2 | Cohort 3 | Cohort 4 | Cohort 5 | Cohort 6 |
|---|---|---|---|---|---|---|
| Baseline | 0.25 ± 0.175 | 0.37 ± 0.343 | 0.41 ± 0.459 | 0.40 ± 0.247 | 0.13 ± 0.129 | 0.09 ± 0.120 |
| Week 2 | 0.39 ± 0.258 | 0.39 ± 0.350 | 0.27 ± 0.184 | 0.42 ± 0.070 | 0.16 ± 0.143 | 0.07 ± 0.120 |
| Week 4 | 0.53 ± 0.294 | 0.42 ± 0.290 | 0.40 ± 0.286 | 0.34 ± 0.135 | 0.62 ± 1.059 | 0.25 ± 0.358 |
| Week 12 | 0.57 ± 0.599 | 0.89 ± 1.223 | 0.70 ± 0.783 | 0.26 ± 0.422 | 0.04 ± 0.028 | 1.19 ± 1.147 |
| Week 20 | 0.24 ± 0.160 | 0.65 ± 0.631 | 0.24 ± 0.141 | 0.13 ± 0.213 | 0.57 ± 0.467 | 0.64 ± 0.593 |
| Week 24 | 0.43 ± 0.454 | 0.45 ± 0.363 | 0.49 ± 0.635 | 0.29 ± 0.325 | 2.14 ± 3.329 | 0.91 ± 0.778 |
| Week 25 | 0.32 ± 0.163 | 0.40 ± 0.237 | 0.18 ± 0.292 | 0.24 ± 0.237 | 1.31 ± 1.168 | 1.36 ± 0.922 |
| Week 36 | 0.21 ± 0.124 | 0.36 ± 0.543 | 0.08 ± 0.068 | 0.79 ± 0.769 | 0.95 ± 0.535 | 0.82 ± 0.303 |
| Week 44 | 0.15 ± 0.164 | 0.35 ± 0.715 | 2.77 ± 3.101 | 1.25 ± 1.268 | 0.65 ± 0.452 | 2.11 ± 1.533 |
| Week 48 | 0.07 ± 0.063 | 0.44 ± 0.551 | 1.87 ± 1.465 | 3.13 ± 5.552 | 0.68 ± 0.773 | 1.23 ± 0.568 |
A blood sample was collected and was sent to the laboratory for analysis of NK cells. Percentage of NK cells per ml of blood. NK cells are lymphocytes with the ability to kill tumor cells without deliberate immunization or activation.
| percentage of cells/mL | Cohort 1 | Cohort 2 | Cohort 3 | Cohort 4 | Cohort 5 | Cohort 6 |
|---|---|---|---|---|---|---|
| Baseline | 6.53 ± 2.829 | 7.22 ± 4.469 | 5.06 ± 2.618 | 7.68 ± 3.724 | 5.04 ± 2.719 | 4.67 ± 1.946 |
| Week 1 Day 2 | 1.98 ± 1.597 | 2.01 ± 2.465 | 2.11 ± 1.386 | 1.38 ± 0.680 | 1.10 ± 0.372 | 1.08 ± 0.980 |
| Week 2 | 7.34 ± 6.862 | 6.03 ± 5.001 | 6.27 ± 1.230 | 7.93 ± 2.861 | 6.17 ± 3.588 | 4.09 ± 1.920 |
| Week 3 Day 15 | 4.99 ± 1.647 | 6.62 ± 5.840 | 5.63 ± 2.792 | 5.93 ± 4.679 | 3.50 ± 1.717 | 4.40 ± 2.570 |
| Week 4 | 6.45 ± 3.189 | 7.88 ± 8.131 | 7.49 ± 2.242 | 5.72 ± 2.458 | 6.12 ± 5.440 | 4.80 ± 3.352 |
| Week 8 | 6.22 ± 4.761 | 7.53 ± 4.347 | 6.79 ± 4.172 | 4.80 ± 2.463 | 4.81 ± 2.573 | 6.21 ± 4.520 |
| Week 12 | 5.47 ± 2.114 | 6.33 ± 3.053 | 6.71 ± 2.328 | 5.25 ± 2.494 | 3.46 ± 1.469 | 5.71 ± 2.446 |
| Week 16 | 10.49 ± 5.747 | 5.28 ± 2.548 | 5.91 ± 3.136 | 5.34 ± 3.057 | 5.58 ± 4.578 | 7.34 ± 6.747 |
| Week 20 | 10.17 ± 7.791 | 4.46 ± 2.638 | 6.81 ± 4.994 | 5.73 ± 2.105 | 5.79 ± 3.144 | 8.03 ± 7.391 |
| Week 24 | 6.70 ± 4.883 | 6.51 ± 3.781 | 5.84 ± 2.890 | 4.55 ± 2.243 | 8.51 ± 5.484 | 9.81 ± 3.968 |
| Week 24 Plus 2 Days | 8.31 ± 9.513 | 4.45 ± 4.072 | 3.75 ± 2.422 | 3.38 ± 1.684 | 5.83 ± 3.711 | 4.97 ± 1.110 |
| Week 25 | 11.45 ± 6.599 | 6.56 ± 4.849 | 5.91 ± 3.133 | 3.71 ± 2.199 | 6.51 ± 3.541 | 8.34 ± 5.602 |
| Week 28 | 8.06 ± 7.674 | 5.47 ± 4.326 | 5.69 ± 3.218 | 4.73 ± 3.334 | 8.29 ± 5.664 | 6.95 ± 2.970 |
| Week 36 | 6.63 ± 3.648 | 6.36 ± 7.256 | 5.72 ± 1.275 | 7.88 ± 5.515 | 8.22 ± 5.772 | 9.58 ± 7.535 |
| Week 40 | 9.17 ± 4.527 | 4.67 ± 3.109 | 5.20 ± 2.904 | 6.18 ± 2.901 | 6.64 ± 3.070 | 6.90 ± 3.244 |
| Week 44 | 7.20 ± 7.764 | 4.40 ± 3.481 | 5.00 ± 1.733 | 8.97 ± 6.008 | 6.59 ± 4.777 | 7.14 ± 3.195 |
| Week 48 | 3.84 ± 2.081 | 5.23 ± 4.943 | 6.72 ± 1.960 | 6.94 ± 3.601 | 7.05 ± 4.446 | 6.10 ± 1.930 |
Plasma concentration is defined as the measured concentration of ublituximab.
No measurements were reported for this outcome.
Collected over From the first dose of study medication through the end of the study (Up to 48 weeks). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Cohort 1 | 0/8 (0%) | 0/8 (0%) | 8/8 (100%) |
| Cohort 2 | 0/8 (0%) | 1/8 (12.5%) | 7/8 (87.5%) |
| Cohort 3 | 0/8 (0%) | 2/8 (25%) | 8/8 (100%) |
| Cohort 4 | 0/8 (0%) | 0/8 (0%) | 8/8 (100%) |
| Cohort 5 | 0/8 (0%) | 0/8 (0%) | 8/8 (100%) |
| Cohort 6 | 0/8 (0%) | 2/8 (25%) | 8/8 (100%) |
| Placebo | 0/13 (0%) | 0/13 (0%) | 12/13 (92.3%) |
| Event | Cohort 1 | Cohort 2 | Cohort 3 | Cohort 4 | Cohort 5 | Cohort 6 | Placebo |
|---|---|---|---|---|---|---|---|
| SeizureNervous system disorders | 0/8 | 0/8 | 1/8 | 0/8 | 0/8 | 0/8 | 0/13 |
| DiverticulumGastrointestinal disorders | 0/8 | 0/8 | 1/8 | 0/8 | 0/8 | 0/8 | 0/13 |
| CholelithiasisHepatobiliary disorders | 0/8 | 0/8 | 1/8 | 0/8 | 0/8 | 0/8 | 0/13 |
| AppendicitisInfections and infestations | 0/8 | 0/8 | 0/8 | 0/8 | 0/8 | 1/8 | 0/13 |
| PregnancyPregnancy, puerperium and perinatal conditions | 0/8 | 1/8 | 0/8 | 0/8 | 0/8 | 0/8 | 0/13 |
| Pregnancy of partnerSocial circumstances | 0/8 | 0/8 | 0/8 | 0/8 | 0/8 | 1/8 | 0/13 |
| Event | Cohort 1 | Cohort 2 | Cohort 3 | Cohort 4 | Cohort 5 | Cohort 6 | Placebo |
|---|---|---|---|---|---|---|---|
| NauseaGastrointestinal disorders | 0/8 | 3/8 | 1/8 | 0/8 | 0/8 | 5/8 | 2/13 |
| FatigueGeneral disorders | 0/8 | 3/8 | 2/8 | 4/8 | 2/8 | 3/8 | 5/13 |
| HeadacheNervous system disorders | 2/8 | 3/8 | 1/8 | 2/8 | 2/8 | 2/8 | 2/13 |
| HypoaesthesiaNervous system disorders | 2/8 | 2/8 | 0/8 | 0/8 | 0/8 | 3/8 | 1/13 |
| DizzinessNervous system disorders | 0/8 | 3/8 | 0/8 | 0/8 | 1/8 | 3/8 | 3/13 |
| Upper respiratory tract infectionInfections and infestations | 2/8 | 0/8 | 1/8 | 1/8 | 3/8 | 0/8 | 1/13 |
| SinusitisInfections and infestations | 1/8 | 0/8 | 1/8 | 3/8 | 0/8 | 0/8 | 2/13 |
| NasopharyngitisInfections and infestations | 0/8 | 0/8 | 1/8 | 3/8 | 0/8 | 1/8 | 0/13 |
| DysphagiaGastrointestinal disorders | 0/8 | 1/8 | 0/8 | 0/8 | 3/8 | 0/8 | 2/13 |
| Back painMusculoskeletal and connective tissue disorders | 3/8 | 1/8 | 0/8 | 1/8 | 0/8 | 1/8 | 0/13 |
Intent-to-Treat (ITT) population included all participants who received at least one dose of ublituximab.
| Age, Continuous(years) | Cohort 1 | Cohort 2 | Cohort 3 | Cohort 4 | Cohort 5 | Cohort 6 | Total |
|---|---|---|---|---|---|---|---|
| Mean | 42.4 ± 12.09 | 34.3 ± 9.13 | 44.9 ± 9.06 | 35.1 ± 9.22 | 43.5 ± 6.39 | 36.5 ± 8.33 | 39.4 ± 9.70 |
| Sex: Female, Male(Participants) | Cohort 1 | Cohort 2 | Cohort 3 | Cohort 4 | Cohort 5 | Cohort 6 | Total |
|---|---|---|---|---|---|---|---|
| Female | 5 | 6 | 5 | 5 | 8 | 3 | 32 |
| Male | 3 | 2 | 3 | 3 | 0 | 5 | 16 |
| Ethnicity (NIH/OMB)(Participants) | Cohort 1 | Cohort 2 | Cohort 3 | Cohort 4 | Cohort 5 | Cohort 6 | Total |
|---|---|---|---|---|---|---|---|
| Hispanic or Latino | 0 | 2 | 1 | 2 | 1 | 3 | 9 |
| Not Hispanic or Latino | 8 | 6 | 7 | 6 | 7 | 5 | 39 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Race/Ethnicity, Customized(Participants) | Cohort 1 | Cohort 2 | Cohort 3 | Cohort 4 | Cohort 5 | Cohort 6 | Total |
|---|---|---|---|---|---|---|---|
| Race — Black or African American | 2 | 0 | 2 | 2 | 0 | 1 | 7 |
| Race — White | 6 | 7 | 6 | 6 | 8 | 6 | 39 |
| Race — Other | 0 | 1 | 0 | 0 | 0 | 1 | 2 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Undecided — Data will be shared after study completion via publication
Ran from May 2016 to primary completion in Sep 2017, 16 months.
Results were first posted in Jul 2021, 3 years 9 months after primary completion.
Of 43 industry-sponsored phase 2 interventional studies under Multiple Sclerosis, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 47. This study's 16 months is below that.
Counting every sponsor, half of 92 studies reached it within 36 months; a quarter within 19 and three quarters within 64.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ublituximab